These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36658421)

  • 1. Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy.
    Ricotti V; Kadirvelu B; Selby V; Festenstein R; Mercuri E; Voit T; Faisal AA
    Nat Med; 2023 Jan; 29(1):95-103. PubMed ID: 36658421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Challenges of Using Patient-Level Claims and Electronic Health Record Data for the Longitudinal Evaluation of Duchenne Muscular Dystrophy Outcomes.
    Gooch KL; Audhya I; Ricchetti-Masterson K; Szabo SM
    Adv Ther; 2024 Sep; 41(9):3615-3632. PubMed ID: 39080221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.
    Lennie JL; Mondick JT; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):91-104. PubMed ID: 31960231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eteplirsen Treatment for Duchenne Muscular Dystrophy: A Qualitative Patient Experience Study.
    Iff J; Carmichael C; McKee S; Sehinovych I; McNeill C; Tesi-Rocha C; Henricson E; Muntoni F; Kitchen H
    Adv Ther; 2024 Aug; 41(8):3278-3298. PubMed ID: 38958840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy.
    Bendixen RM; Lott DJ; Senesac C; Mathur S; Vandenborne K
    Disabil Rehabil; 2014; 36(22):1918-23. PubMed ID: 24499260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies.
    Spitali P; Hettne K; Tsonaka R; Charrout M; van den Bergen J; Koeks Z; Kan HE; Hooijmans MT; Roos A; Straub V; Muntoni F; Al-Khalili-Szigyarto C; Koel-Simmelink MJA; Teunissen CE; Lochmüller H; Niks EH; Aartsma-Rus A
    J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):715-726. PubMed ID: 29682908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials.
    Servais L; Yen K; Guridi M; Lukawy J; Vissière D; Strijbos P
    J Neuromuscul Dis; 2022; 9(2):335-346. PubMed ID: 34958044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European regulators' views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials.
    Haberkamp M; Moseley J; Athanasiou D; de Andres-Trelles F; Elferink A; Rosa MM; Magrelli A
    Neuromuscul Disord; 2019 Jul; 29(7):514-516. PubMed ID: 31272741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials.
    Ricotti V; Evans MR; Sinclair CD; Butler JW; Ridout DA; Hogrel JY; Emira A; Morrow JM; Reilly MM; Hanna MG; Janiczek RL; Matthews PM; Yousry TA; Muntoni F; Thornton JS
    PLoS One; 2016; 11(9):e0162542. PubMed ID: 27649492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Association Between Physical Activity/Heart Rate Variability Data Obtained Using a Wearable Device and Timed Motor Functional Tests in Patients with Duchenne Muscular Dystrophy: A Pilot Study.
    Nakamura A; Matsumura T; Takeshima Y; Kuru S; Imazaki M; Nonomura H; Kaiya H
    J Neuromuscul Dis; 2024; 11(3):715-724. PubMed ID: 38607760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobile arm supports in Duchenne muscular dystrophy: a pilot study of user experience and outcomes.
    Cruz A; Callaway L; Randall M; Ryan M
    Disabil Rehabil Assist Technol; 2021 Nov; 16(8):880-889. PubMed ID: 32293211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroids for the treatment of Duchenne muscular dystrophy.
    Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel free-circulating and extracellular vesicle-derived miRNAs dysregulated in Duchenne muscular dystrophy.
    Catapano F; Scaglioni D; Maresh K; Ala P; Domingos J; Selby V; Ricotti V; Phillips L; Servais L; Seferian A; Groot I; Krom YD; Voit T; Verschuuren JJGM; Niks EH; Straub V; Morgan J; Muntoni F
    Epigenomics; 2020 Nov; 12(21):1899-1915. PubMed ID: 33215544
    [No Abstract]   [Full Text] [Related]  

  • 14. Quantitative muscle MRI biomarkers in Duchenne muscular dystrophy: cross-sectional correlations with age and functional tests.
    Sherlock SP; Zhang Y; Binks M; Marraffino S
    Biomark Med; 2021 Jun; 15(10):761-773. PubMed ID: 34155911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T
    Maforo NG; Magrath P; Moulin K; Shao J; Kim GH; Prosper A; Renella P; Wu HH; Halnon N; Ennis DB
    J Cardiovasc Magn Reson; 2020 Dec; 22(1):85. PubMed ID: 33302967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A wearable motion capture suit and machine learning predict disease progression in Friedreich's ataxia.
    Kadirvelu B; Gavriel C; Nageshwaran S; Chan JPK; Nethisinghe S; Athanasopoulos S; Ricotti V; Voit T; Giunti P; Festenstein R; Faisal AA
    Nat Med; 2023 Jan; 29(1):86-94. PubMed ID: 36658420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy.
    Signorelli M; Ayoglu B; Johansson C; Lochmüller H; Straub V; Muntoni F; Niks E; Tsonaka R; Persson A; Aartsma-Rus A; Nilsson P; Al-Khalili Szigyarto C; Spitali P
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):505-517. PubMed ID: 31881125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health.
    Bendixen RM; Senesac C; Lott DJ; Vandenborne K
    Health Qual Life Outcomes; 2012 May; 10():43. PubMed ID: 22545870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life of patients with Duchenne muscular dystrophy: from adolescence to young men.
    Lue YJ; Chen SS; Lu YM
    Disabil Rehabil; 2017 Jul; 39(14):1408-1413. PubMed ID: 27347814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.